Loading...
FHTX logo

Foghorn Therapeutics Inc.NasdaqGM:FHTX 株式レポート

時価総額 US$286.5m
株価
n/a
1Y1.2%
7D22.8%
1D2.7%
ポートフォリオ価値
​
表示

Foghorn Therapeutics Inc.

NasdaqGM:FHTX 株式レポート

時価総額：US$286.5m

Foghorn Therapeutics（FHTX）株式概要

フォグホーン・セラピューティクス社は臨床段階のバイオ医薬品会社で、米国においてクロマチン調節システム内の遺伝的に決定された依存性を標的とする医薬品の発見と開発に従事している。 詳細

FHTX ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長2/6
過去の実績0/6
財務の健全性3/6
配当金0/6

報酬

収益は年間35.94%増加すると予測されています

過去5年間の収益は年間5.2%増加しました。

アナリストらは、株価が128.4%上昇するだろうとほぼ一致している。

リスク分析

マイナスの株主資本

現在は利益が出ておらず、今後3年間で利益が出る見込みはない


FHTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW488,589 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
IN
Investingwilly
BL
BlackGoat
RO
RockeTeller
AG
Agricola
488,589 investors already sharing narratives
View all narratives

Foghorn Therapeutics Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Foghorn Therapeutics
過去の株価
現在の株価US$5.01
52週高値US$6.95
52週安値US$3.27
ベータ2.89
1ヶ月の変化26.04%
3ヶ月変化1.62%
1年変化1.21%
3年間の変化-26.86%
5年間の変化-51.97%
IPOからの変化-72.35%

最新ニュース

分析記事 • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...

Recent updates

分析記事 • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...
分析記事 • Dec 23

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
分析記事 • Dec 19

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Sep 07

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jul 10

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon

With a price-to-sales (or "P/S") ratio of 13.1x Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be sending very bearish...
分析記事 • Apr 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has fared very poorly over the last month, falling by a...
Seeking Alpha • Mar 26

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients

Summary Foghorn Therapeutics remains a "hold" due to ongoing development of FHD-909 for SMARCA4 solid tumors, with key data expected by late 2025/early 2026. Partnership with Eli Lilly strengthens FHD-909's prospects, focusing on NSCLC patients with SMARCA4 mutation & other programs; Upfront $380 million payment and up to $1.3 billion milestone payments. Preclinical results of FHD-909 combined with KEYTRUDA and KRAS inhibitors will be presented at AACR in April 2025, offering an early catalyst. The global non-small lung carcinoma market is predicted to reach $21.51 billion by the end of 2033; Up to 10% of NSCLC solid tumors express SMARCA4 mutation. Read the full article on Seeking Alpha
分析記事 • Feb 23

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are no doubt pleased to see that the share price has bounced 29...
分析記事 • Feb 08

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jan 01

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders that were waiting for something to happen have been dealt a blow...
分析記事 • Nov 07

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) just released its third-quarter report and things are looking bullish...
分析記事 • Oct 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has softened a substantial 28% over the previous 30 days...
分析記事 • Sep 01

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has done very well over the last month, posting an excellent...
分析記事 • Jul 17

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares have had a really impressive month, gaining 27% after a shaky period...
分析記事 • May 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are probably feeling a little disappointed, since its shares...
分析記事 • Apr 12

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Feb 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
分析記事 • Dec 13

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 33...
分析記事 • Nov 07

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Shareholders in Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be thrilled to learn that the analysts have just...
分析記事 • Jun 14

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 10

Foghorn Therapeutics: Selling For Less Than Cash Value

Summary Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the balance sheet. An investment analysis follows in the paragraphs below. One of the advantages of being disorganized is that one is always having surprising discoveries.”― A.A. Milne Today, we take our first look at Foghorn Therapeutics Inc. (FHTX). This small biotech concern came public in 2020 and now finds itself in Busted IPO territory. In a testament to how cruel 2022 has been to small biotech concerns, Foghorn is one of myriad biotech stocks that currently trade for less than the net cash on its balance sheet. The company does have a bevy of early stage drug candidates currently in development. An analysis follows below. Seeking Alpha Company Overview: Foghorn Therapeutics is based just outside of Boston in Cambridge, MA. This clinical-stage biopharmaceutical company is focused on developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company develops drug candidates utilizing its proprietary Gene Traffic Control platform that identifies and validates potential drug targets within the system. The stock currently trades for just over $8.00 a share and sports an approximate market capitalization of $330 million. September Company Presentation The company is utilizing enzyme inhibition and protein degradation approaches to potentially treat cancers, including uveal melanoma and synovial sarcoma. Foghorn is targeting one of the ways cells regulate gene expression by using chromatin in the so-called chromatin gene regulatory system. It has dubbed this approach "Gene Traffic Control." Foghorn has developmental partnership deals with drug giants Merck (MRK) and Eli Lilly (LLY). The partnership with Loxo Oncology, a division of Lilly, brought in a $380 million upfront payment. The one with Merck consisted of a $15 million upfront payment as well as a potential $410 million in various milestone payouts. September Company Presentation As you can see above, most of the candidates within Foghorn's pipeline are early staged and partnered with larger drug players. One of its wholly owned candidates is FHD-286. This compound is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM and is targeting multiple indications. September Company Presentation FHD-286 is in Phase I development. Unfortunately, in late August the FDA slapped a full clinical hold on the Foghorn's phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia ((AML)) and myelodysplastic syndrome [MDS]. This follows a partial hold issued in May and comes as a result of additional suspected cases of fatal differentiation syndrome. The FDA has questions, and this will require further analysis before the hold could be potentially lifted. A Phase 1 dose escalation study of FHD-286 in metastatic uveal melanoma (mUM) will continue as plan. Initial results from this trial should be out in the first half of 2023. September Company Presentation The company is currently enrolling patients in a Phase 1 clinical study evaluating FHD-609 in synovial sarcoma is also due out in 2023. FHD-609 is a potent and selective heterobifunctional protein degrader of BRD9. September Company Presentation All the partnered candidates in Foghorn's pipeline are in even earlier stages of development. The company did receive $4.5 million worth of collaboration revenue via its partnership with Loxo Oncology in the second quarter and will receive a $5 million milestone payout from Merck in the third quarter. Analyst Commentary & Balance Sheet: So far in 2022, Wedbush, Goldman Sachs ($21 price target) and H.C. Wainwright ($25 price target) have reissued Buy ratings on Foghorn Therapeutics, while Morgan Stanley ($15 price target) has maintained a Hold rating on the stock.
Seeking Alpha • Aug 23

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

The U.S. Food and Drug Administration (FDA) placed a full clinical hold on Foghorn Therapeutics' (NASDAQ:FHTX) phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after additional suspected cases of fatal differentiation syndrome. The FDA had placed partial hold on the study in May following the report of a death due to a potential differentiation syndrome. The company said in an Aug. 23 press release that the full clinical hold in the study was due to the observation, in the data submitted in response to the partial hold, of additional suspected cases of fatal differentiation syndrome believed to be linked with FHD-286. Foghorn added that Differentiation syndrome is linked with AML/MDS therapies which induce differentiation, an effect that has been seen with, and is believed to be on-target for, the proposed mechanism of action for FHD-286. The FDA has additional questions and requires further analyses before the clinical hold may be lifted, the company noted. Foghorn said that a dose escalation phase 1 trial of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol and it plans to report data in H1 2023. FHTX -18.38% to $11.99 premarket Aug. 23
Seeking Alpha • Aug 09

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Foghorn Therapeutics press release (NASDAQ:FHTX): Q2 GAAP EPS of -$0.66 misses by $0.07. Revenue of $4.49M (+1503.6% Y/Y).
Seeking Alpha • Jun 02

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have. If they can do proof of concept, they may go up considerably.
分析記事 • Apr 13

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

株主還元

FHTXUS BiotechsUS 市場
7D22.8%3.7%1.6%
1Y1.2%37.9%21.1%

業界別リターン: FHTX過去 1 年間で40 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: FHTXは、過去 1 年間で20.3 % のリターンを上げたUS市場を下回りました。

価格変動

Is FHTX's price volatile compared to industry and market?
FHTX volatility
FHTX Average Weekly Movement9.6%
Biotechs Industry Average Movement10.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

安定した株価: FHTX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: FHTXの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2015106Adrian H. Gottschalkfoghorntx.com

フォグホーン・セラピューティクス社は臨床段階のバイオ医薬品会社で、米国においてクロマチン制御システム内の遺伝的に決定された依存性を標的とした医薬品の発見と開発に従事している。同社は、独自のGene Traffic Controlプラットフォームを用いて、クロマチン制御システム内の創薬標的を同定、検証し、創薬の可能性を探っている。現在、変異型がん、非小細胞肺がん、子宮内膜がん、子宮頸がん、卵巣がん、膀胱がん、びまん性大細胞型B細胞リンパ腫、各種急性骨髄性白血病、骨髄異形成症候群の治療薬を開発している。同社は、BRMの選択的ATPase阻害剤であるFHD-909の開発に関してイーライリリー・アンド・カンパニーと共同研究契約を結んでいる。同社は2015年に法人化され、マサチューセッツ州ウォータータウンに本社を置いている。

Foghorn Therapeutics Inc. 基礎のまとめ

Foghorn Therapeutics の収益と売上を時価総額と比較するとどうか。
FHTX 基礎統計学
時価総額US$286.52m
収益（TTM）-US$75.32m
売上高(TTM)US$28.22m
10.4x
P/Sレシオ
-3.9x
PER（株価収益率

FHTX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
FHTX 損益計算書（TTM）
収益US$28.22m
売上原価US$82.10m
売上総利益-US$53.87m
その他の費用US$21.45m
収益-US$75.32m

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）-1.28
グロス・マージン-190.88%
純利益率-266.88%
有利子負債／自己資本比率0%

FHTX の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/01 08:45
終値2026/07/01 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Foghorn Therapeutics Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15

アナリスト機関
Yuan ZhiB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Suranjit MukherjeeBTIG